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Objective: To investigate whether a change in current treatment practice for Staphylococcus aureus bacteremia from 
flucloxacillin and aminoglycoside to flucloxacillin and fusidic acid was associated with any changes in outcome. 
Methods: A retrospective analysis was carried out of 316 episodes of S. aureus bacteremia diagnosed and treated in 
a tertiary hospital complex between 1983 and 1993. Outcomes considered were (1) death related to the infection and (2) 
relapse following cessation of antibiotic therapy. 
Results: Mortality related to infection, which occurred in 24% of patients, was unrelated to treatment with the 
combination of flucloxacillin and fusidic acid; however, increasing age was a significant risk factor (OR per decade = 
1.35, 95% CI = 1.1&1.55), and increasing duration of treatment (OR per week of treatment = 0.63,95% CI = 0.52-0.77), 
use of flucloxacillin (OR = 0.30,95% CI = 0.14-0.64). presence of an intravascular device (OR = 0.39,95% CI = 0.20-0.78) 
and presence of a skin lesion (OR = 0.51, 95% CI = 0.26-0.99) were significant protective factors. The only factor 
significantly related to relapse, which occurred in 11% of patients, was treatment with the combination of flucloxacillin 
and fusidic acid (OR = 0.32, 95% CI = 0.12-0.85). There was approximately a 70% reduction in the risk of relapse if this 
combination was used. 
Conclusions: This retrospective analysis suggests a clinically important protective effect of fusidic acid against relapse 
in patients with S. aureus bacteremia. Although the results were adjusted for potential confounding factors, the 
possibility of bias remains. There is a need for a prospective randomized trial to evaluate the effectiveness of 
flucloxacillin and fusidic acid for treating S. aureus bacteremia. 
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INTRODUCTION 
Staphylococcus aureus is the most fiequent cause of 
bacteremia due to Gram-positive bacteria and the 
commonest cause of wound infection in the UK. The 
reported mortality associated with S.  aureus bacteremia 
ranges fiom 21% to 43% [l-51. Factors that preckspose 
to infection with S. aureus include breaches in the skin 
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and the presence of foreign bodies, although infection 
may arise without a predisposing factor. Infection with 
S. aureus is frequently associated with bacteremia and 
metastatic disease [6-81. 
Conflicting observations have resulted in un- 
certainty concerning the optimum duration of anti- 
biotic therapy for bacteremia caused by S. aureus [8]. 
Many believe that a l l  patients with S. aureus bacteremia 
should be treated with a 4-6 week course of intra- 
venous antibiotics [9,10] in order to prevent serious 
sequelae such as endocarditis. Recently, some authors 
have suggested that shorter courses of therapy for 
catheter-related bacteremia and uncomplicated right- 
sided endocarditis in intravenous drug users would be 
adequate [ll-161, whereas others have maintained that 
short-course therapy results in unacceptable rates of 
complication and relapse [17,18]. 
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Fusidic acid is frequently used in the UK but rarely 
in the USA [19,20]. Use of fusidic acid was not 
emphasized in the laboratory recommendations for 
the treatment of S. aureus bacteremia in the United 
Bristol Hospital Trust (UBHT) complex of hospitals 
until 1991, when a laboratory recommendation of 
flucloxacillin and fusidic acid, given as the sodium salt 
for 4 weeks, was introduced. 
At dus time it was felt that an antibiotic combina- 
tion including hs idc  acid would, because of its better 
tissue penetration, offer benefit in terms of outcome for 
the patient over a combination involving an amino- 
glycoside. We report a review of the outcome of 
patients treated for S. aureus bacteremia in the UBHT 
between 1983 and 1993 with particular emphasis on 
the impact of the use of fusidic acid. 
PATIENTS AND METHODS 
Data were collected by a retrospective review of case 
records for patients diagnosed and treated for S. aureus 
bacteremia between January 1983 and December 1993 
in the UBHT hospital complex. These hospitals form 
a large teaching hospital unit with regional specialities 
including cardiac surgery, oncology services and neo- 
natal intensive care. In 1993, 54 000 inpatients were 
treated in the UBHT. In addtion to drawing patients 
from the central and south Bristol areas, it also acts as 
a referral centre for the southwest of England. The 
Bristol catchment population was 361 000 in 1983, 
rising to 370 000 in 1991 (estimates based on Office 
of Population and Censuses Surveys 1993 mid-year 
population). 
The UBHT cases were identified by searching 
laboratory records of blood cultures, collected between 
January 1983 and December 1993, from which S. 
aureus had been grown. Patients with no clinical diag- 
nosis of infection and who were not treated for 
infection, and those with polymicrobial bacteremia 
without corroborating clinical or laboratory evidence 
of S. aureus infection, were excluded. 
The method of obtaining blood cultures changed 
in July 1988. Prior to 1988, blood cultures were 
performed by inoculation of 5-10 d of aseptically 
drawn blood into brain-heart infusion (Oxoid CM 
225, Unipath Ltd, Basingstoke) and thioglycollate 
broths. Broth cultures were subcultured onto solid 
media afker 2 and 7 days. After July 1988 a commercial 
automated blood culture system was adopted (Bactec 
660, Becton Dickinson UK Ltd, Oxford). Identifica- 
tion of S. aureus was carried out by standard methods 
[21]. Antibiotic susceptibility was determined by Stokes' 
method for the following antibiotics: penicillin, genta- 
micin, fusidic acid and erythromycin [22]. Suscepti- 
bility to methicillin was determined with a paper 
strip containing 25 pg methicillin, on blood agar and 
mannitol salt plates incubated at 30°C and 37OC 
respectively. 
Demographic data recorded from the notes 
included date of birth, sex, age at time of the positive 
blood culture, and whether infection was acquired in 
the community or the hospital. Associated condtions 
whch might influence outcome, such as malignancy, 
diabetes mellitus, rheumatoid arthritis, cardiac disease, 
intravenous drug use and immunosuppression (asplenia, 
steroid therapy, neutropenia, cytotoxic therapy), were 
documented. Possible risk factors for infection, such 
as bone fracture, skin lesions, transcutaneous foreign 
bodies, operation within the previous year, prosthetic 
joints, bone screws and nails and prosthetic heart valves, 
were also recorded. Microbiological data included the 
date of the positive blood culture, and whether S. aureus 
was isolated &om the respiratory tract, urinary tract, 
skin/wound lesions or intravascular line tips. Treatment 
information recorded included antibiotics and their 
duration of use. 
Information about the outcome of treatment 
included the date of death, whether death was related 
to infection and whether a relapse occurred. The 
infection was classified as community acquired if the 
blood cultures had been collected within 48 h of 
hospital admission &om the community and as hospital 
acquired in all other cases. A relapse was said to have 
occurred if a patient developed a new suppurative 
complication or blood culture with S. aureus within 5 
years following cessation of antibiotic therapy. In 92% 
of cases, relapse occurred within 10 months. Phage 
typing was documented in only three cases and showed 
identical phage types for both isolates. Antibiotic 
susceptibility profiles were identical in all cases with the 
exception of one. Death was considered to be related 
to infection (DRI) if the death resulted from acute 
sepsis syndrome or a complication of S. aureus 
bacteremia, such as endocarditis. Post-mortem data 
were used when available. 
Information recorded fi-om the notes was trans- 
ferred to a database. Descriptive statistics for demo- 
graphic and relevant clinical data were calculated, 
including the proportions of patients receiving fusidic 
acid and the proportion experiencing the outcomes of 
interest, in each year. The effects of various clinical 
factors and treatment combinations on each outcome 
were then investigated in more detail by statistical 
modeling using multiple logistic regression, allowing 
estimates of odds ratios (ORs) for different factors to 
be obtained with and without adjustment for possible 
confounding variables. 
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RESULTS 
The total number of patients for whom blood cultures 
were requested &om 1985 to 1993 was 66 447 and 
requests showed an upwards trend from 6523 in 1985 
to 9193 in 1993. Data for total requests were unobtain- 
able for 1983 and 1984, as laboratory computerization 
was not implemented until 1985. The annual total of 
all patients with positive blood cultures rose from 437 
in 1985 to 739 in 1993, but the proportion positive for 
S. aureus remained constant at approximately 11% of 
the total. Between January 1983 and December 1993, 
522 patients with blood cultures positive for S. aureus 
were identified from manual and computer records. 
From h s  initial total, 206 (39.5%) were excluded or 
not evaluated; case records were unavailable for 100 
(19.2%), 26 (5%) had polymicrobial sepsis and 80 
(15.3%) showed no clinical evidence of infection (Table 
The following analyses are therefore based on the 
data h m  316 patients with new episodes of S. aureus 
bacteremia, 94.7% of whom were admitted &om the 
Bristol catchment area. The distribution of patients 
for whom memcal records were not available was 
examined by calendar year, age, gender, admitting 
hospital and year of admission. Some records were 
unobtainable for each year throughout the study and 
ranged from four patients in 1983 to a maximum of 17 
patients in 1991. There was no trend over time (see 
Table l), or any indication &om consideration of other 
variables that patients for whom records were missing 
were different h m  those for whom data were available. 
1). 
The number of cases in each year ranged from 15 
to 45. There appeared to be an increase in the number 
of cases occurring over time, paralleling the increase in 
total requests and positive blood cultures, despite an 
essentially constant catchment population (x2=23.65, 
degrees of fieedom 10, p<O.Ol; linear regression of 
number of cases against time gave a p coefficient for 
each year of 1.95 cases, p=0.004). These trends may 
have been due to better detection of cases, better use 
of the laboratory or a real increase in numbers of cases. 
The median age was 51.6 years with an inter- 
quartile range (41-43) of 20.8-68.5 years. However, 
the distribution of age was bimodal, with peaks in the 
mstribution amongst both young and elderly. The >65 
age group accounted for almost one third of cases. 
Staphylococcal bacteremia aEected both sexes but there 
was a slight preponderance of males: 178 (56%) of the 
cases were male and 138 (44%) of the cases were female. 
Infection was classified as hospital acquired in 166 
(S3%) of the cases and as community acquired in the 
remaining 150 (47%). There was no evidence of a trend 
with time during the study period for either of these 
factors. 
Antibiotic susceptibility 
Most isolates were resistant to penicillin only (87%). 
Resistance to methlcillin, gentamicin or hsidic acid 
was rare (0.9% for each of the antibiotics). Erythro- 
mycin resistance occurred in 4% of isolates. Multiple 
resistance was also unusual, with only 0.9% of isolates 
resistant to three or more of the antibiotics tested; these 
were all methicillin-resistant strains of S. aureus. 
Table 1 The distribution of positive blood cultures over the period of the study, the number of S. aweus cases in each of the 
years studied, the number of missing records, those not clinically sigruficant and the number of patients who experienced the 
two outcomes of interest 
s. I ( u m  cases 
Missing included Dying from Blood cultures Not clinically 
Relapse infection positive for significant records in study 
Year S. aureus n (%y n (%y n (%y n (%)b n (%)b 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
Total 
27 
22 
52 
53 
48 
56 
45 
45 
57 
50 
67 
522 
23 (85) 
15 (68) 
32 (62) 
21 (40) 
31 (55) 
31 (69) 
31 (69) 
35 (61) 
'31 (62) 
45 (67) 
316 (61) 
21 (44) 
'Percentages of the total number of cases with blood cultures positive for S. nureus in the year. 
bPercentages of the number of cases included in the study &om the year. 
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Antibiotic therapy 
The number and type of antibiotics used in each patient 
for the definitive treatment of S. aureus bacteremia once 
blood culture results were known were analyzed. One 
hundred and forty-nine (47%) of the patients received 
two different antibiotics. Twenty (6%) of the patients 
received no antibiotic treatment, 57 (18%) received one 
antibiotic, 63 (20%) received three antibiotics, 22 (7%) 
received four antibiotics and five (1%) of the patients 
received five antibiotics. 
Flucloxacillin was the preferred antibiotic and was 
used in 251 (79%) of the patients. Other antibiotics 
used included fusidic acid (38%), aminoglycosides 
(32%), cephalosporins (17%), erythromycin (7%), 
vancomycin (6%) and clindamycin (0.9%). In patients 
who received flucloxacillin it was used alone in 421251 
(17%) of these patients. Combination therapy was used 
in the remainder, with the addition of fusidic acid in 
108/251 (43%), of aminoglycosides in 86/251 (34%), 
or of another antibiotic in 15/251 (6%). Twenty-two 
(9%) of the patients treated with flucloxacillin received 
both aminoglycosides and fusidic acid during therapy, 
but not simultaneously. 
Figure 1 shows the pattern of use of flucloxacillin 
with fusidic acid or an aminoglycoside from 1983 to 
1993. The numbers of patients who received the two 
commonest treatment combinations, flucloxacillin plus 
1 
n 
UJ 
Q) 
UJ 
G 
aminoglycoside and flucloxacillin plus fusidic acid, with 
or without additional antibiotics, are shown in Table 2. 
Also shown are the numbers of patients who received 
flucloxacillin alone and of those who did not receive 
any flucloxacillin. Figure 1 shows that the use of 
flucloxacillin remained hlgh during the study period. 
Although the total number of patients receiving either 
fusidlc acid or an aminoglycoside in combination with 
flucloxacillin remained fairly constant during the study 
period, the frequencies with which each combination 
was used changed over time. Use of fusidic acid 
decreased from 1984 until 1987 but increased there- 
after, with a more dramatic rise in 1991 following the 
introduction of guidelines. Use of aminoglycosides 
remained fairly constant from 1983 to 1987, and then 
declined in parallel with the increase in use of fusidic 
acid. 
The types of aminoglycoside used were gentamicin 
in adult patients and nedmicin in pediatric patients. If 
aminoglycosides were used, serum levels were con- 
sidered adequate if the post-dose was >6 mg/L on at 
least one.occasion when a multiple dosing regimen was 
used. Levels were adequate in 57/101 (56%) of the 
patients and inadequate in 26/101 (26%) of the patients. 
In the remaining 18 cases aminoglycoside levels were 
either not documented or not taken. Antibiotics were 
discontinued because of drug side effects in only 24 
8 .  
O X  1 
1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 
Year 
Flucloxacillin 
Fusidic acid 
Aminoglycoside 
Figure 1 Treatment of S. aureuS bacteremia with flucloxacillin and with fusidic acid or aminoglycoside, &om 1983 to 1993. 
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Table 2 Numbers of patients who received the commonest treatment regimens 
FLU plus FLU plus 
FUS N S  AMINO AMINO 
with or with or with or with or FLU 
without without without without FLU Plus OTH 
Year Cases' OTH OTH OTH OTH alone OTH ornone 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
Total 
23 
15 
32 
21 
21 
31 
31 
31 
35 
31 
45 
316 
7 
5 
4 
3 
7 
8 
10 
7 
8 
20 
29 
108 
3 
2 
1 
0 
0 
0 
1 
1 
2 
1 
2 
13 
10 
7 
11 
10 
10 
10 
8 
11 
5 
1 
3 
86 
1 
0 
5 
0 
0 
2 
1 
2 
3 
0 
1 
15 
1 
2 
5 
4 
2 
5 
7 
3 
5 
5 
3 
42 
0 
1 
3 
2 
2 
6 
4 
6 
8 
2 
1 
35 
5 
0 
5 
3 
2 
2 
2 
5 
5 
2 
8 
39 
FLU= flucloxacillin; FUS=fusidic acid; AMINO=gentamicin or netilmicin; OTH= other antibiotic. 
'Some cases are included in more than one column, e.g. when a patient received flucloxacillin and h id i c  acid and flucloxacillin and 
aminoglycoside at Merent times during treatment. 
patients. Antibiotics were discontinued in seven patients 
on aminoglycosides (renal toxicity), nine patients on 
fusidic acid (rash 1, jaundice 6, vomiting 1, fluid 
overload l), six patients on flucloxacillin (rash) and one 
patient on cephalosporins (rash); and in one patient 
both flucloxacillin and fusidic acid were discontinued 
(rash). 
The median duration of antibiotic treatment for 
316 bacteremic patients was 15 days (41-Q3=8-29) 
and almost 90% of patients were treated for less than 6 
weeks. 
Factors related to treatment outcomes 
The numbers of patients who experienced the two 
outcomes of interest in each year during the study 
period are shown in Table 3. Two hundred and forty- 
eight (78%) of the patients survived the infective 
episode and showed no residual clinical signs of 
infection. Death related to infection occurred in 75 
(24%) of the patients. There were relatively few 
instances of relapse, which occurred in only 35 (11%) 
of the patients. Twelve patients who relapsed also died 
&om the staphylococcal infection. 
Death related to infection (DRI) 
Risk factors for DRI were investigated in more detail 
using multiple logistic regression. Age and duration 
of treatment were fitted as continuous variables, but 
divided by 10 and 7 respectively to give odds ratios 
(ORs) per decade and per week. The odds of DRI 
increased significantly with increasing age, but de- 
creased with increasing duration of treatment (Table 4). 
The possibihty of an increased risk of DRI amongst 
both the young and elderly was investigated by fitting 
a quadratic term, but dus did not increase the likeli- 
hood ratio significantly. Year of treatment was also 
considered, but had no significant effect on DRI 
after controlling for age and duration of treatment 
(OR=1.03; confidence intervals (CI)=O.93-1.13), or 
in any subsequent models that were fitted. 
After adjusting for age and duration of treatment, 
four other factors appeared to be independently and 
significantly associated with a reduction in the odds of 
DRI: treatment with flucloxacillin (with or without 
any other antibiotic), infection acquired in the com- 
munity, presence of an intravenous device and presence 
of a skin lesion. When a l l  of these factors were modeled 
Table 3 Numbers of patients who died or relapsed 
Death related 
Year CaSeS Relapse to infection 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
Total 
23 
15 
32 
21 
21 
31 
31 
31 
35 
31 
45 
316 
4 
2 
5 
4 
2 
2 
3 
1 
7 
3 
2 
35 
~ 
5 
3 
9 
5 
5 
4 
9 
8 
8 
8 
11 
75 
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Table 4 Estimates of odds ratios for the factors associated 
with the risk of death related to infection 
Table 5 Estimates of odds ratios for the factors associated 
with the risk of relapse 
95% 
Odds ratio confidence 
(OR) interval (CI) z - d u e  p-value 
Age (per decade) 1.35 1.18-1.55 4.42 <0.001 
Duration of treatment 0.63 0.52-0.77 -4.58 <0.001 
(per week) 
Treatment with 
flucloxacillin 0.3 0.14-0.64 -3.15 0.002 
Presence of IV device 0.39 0.20-0.78 -2.68 0.007 
Presence of slun 
lesions 0.51 0.26-0.99 -1.98 0.048 
together, the factor of community-acquired infection 
failed to reach significance but, from its effect on the 
odds ratios for presence of an intravenous device and 
presence of a skin lesion, appeared to be positively 
associated with these latter two variables. Therefore, 
the final model included age, duration of treatment, 
treatment with flucloxacillin, the presence of an intra- 
venous device and the presence of a skin lesion. ORs 
and CIS for these factors, based on this model, are 
shown in Table 4. 
Because of the particular interest in the treatment 
combination of flucloxacdhn and fusidic acid (with or 
without other antibiotics), a further analysis was carried 
out to compare the risks of DRI in patients who 
received this treatment combination and in those who 
were treated with flucloxacillin alone or in combina- 
tion with any other antibiotics except fusidic acid. In 
this analysis patients who did not receive flucloxacillin 
were excluded. After adjusting for age, duration, 
intravenous device and skin lesion, no significant effect 
was demonstrated for the inclusion of fusidic acid in 
treatment, and the odds ratio estimates for all the other 
factors in the model were essentially the same as those 
shown in Table 4. 
Relapse 
A similar approach was used to investigate risk factors 
for relapse. Although neither age nor duration of 
treatment reached significance, estimates of the effects 
of other factors were always adjusted for these factors 
because one would intuitively expect them to be 
associated with the likelihood of relapse. The only 
factor that appeared to be significantly related to 
relapse was treatment with the combination of fluclo- 
xacillin plus fusidic acid there was approximately a 70% 
reduction in the odds of relapse if this combination 
was used (OR=0.32, 95% CI=0.12-0.85, ~ ~ 0 . 0 2 ) .  
95% 
Odds ratio confidence 
(OR) interval (CI) r-value p d u e  
Age (per decade) 1.06 0.93-1.21 0.86 0.392 
Duration of treatment 1.08 0.98-1.18 1.61 0.107 
(per week) 
Treatment with 
flucloxacdlin 
and fiisidate 0.32 0.12-0.85 -2.28 0.023 
Estimates from the final model of the 0% and CIS for 
age, duration of treatment and treatment with the 
combination of flucloxacdhn and fusidic acid are shown 
in Table 5. 
DISCUSSION 
This retrospective survey of S. aureus bacteremia is the 
only large study reported f?om the UK in the last 10 
years. The risk factors identified were similar to those 
reported in previous studies [4,7]. The total number of 
cases of bacteremia showed an increase during the study 
period. The number of cases attributed to S. aureus as 
a proportion of all causes of bacteremia did not change 
and is similar to national data [23]. Bacteremia with S. 
aureus occurs at all ages, and in our study almost one 
third of cases occurred in the over-65-year age group. 
Infection acquired in hospital occurred in slightly more 
than half of cases, as reported in other studies [4,24]. 
In this study we determined the outcome follow- 
ing treatment of S. aureus bacteremia. Unresolved issues 
relating to the treatment of this condition include 
whether a single antibiotic or a combination of anti- 
biotics should be used, which antibiotic(s) should be 
used and what should be the optimum duration of 
therapy. Whether a single antibiotic or a combination 
of antibiotics is associated with a better outcome for the 
patient is not known. It has been suggested that any 
antibiotic to which the isolate is sensitive, as shown by 
in vitro laboratory testing, would be appropriate [4,25]. 
Animal models have demonstrated that a combination 
of a penicillin with an aminoglycoside is synergistic 
[26,27] and moderately improves the outcome in 
experimental infective endocarditis, but there are no 
data showing a benefit from t h s  qpe  of Combination 
in patients with endocarditis [26]. Some authors 
advocate the use of 2 weeks of an aminoglycoside 
in addition to a p-lactam agent for left-sided S. aureus 
endocarditis but not right-sided endocarditis [28,29]. In 
the UK, combination therapy for S. aureus endocarditis 
38 Clinical Microbio logy and Infection, Volume 3 Number  1, February  1997 
is usually employed. In tlm study 47% of patients 
received two different antibiotics, 18% received one 
antibiotic and 20% received three antibiotics. In 
practice, the latter patients initially received a combina- 
tion of two antibiotics, and another antibiotic was used 
subsequently for completion of the course of therapy. 
Most current treatment regimens for S. aureus suggest 
the parented administration of a penicillinase-resistant 
penicfin as the mainstay of treatment. In the UK, 
both the British National Formulary and the BSAC 
Worlung Party’s recommendations for the treatment of 
staphylococcal endocarditis include fisidic acid [20,30]. 
In Denmark, S. aureus bacteremia would usually be 
treated with fusidic acid in combination with other 
antibiotics such as methicillin or dicloxacdlin [31]. 
American literature does not cite the use of fusidic acid, 
because it is not licensed for use in the USA. 
In this study flucloxacdhn was used in 79% of cases 
and in combination with either an aminoglycoside or 
fusidic acid in 27% and 34% of cases, respectively. The 
results suggest that the rate of death due to S. aureus 
infection remained essentially unchanged over a 10- 
year period, and was unrelated to a change in the 
preferred treatment from flucloxacihn and amino- 
glycoside to flucloxacillin and fusidic acid. This finding 
agrees with other studies which have shown sirmlar 
mortality rates whether or not fusidic acid was used for 
therapy [32]. Increasing age was a significant risk factor 
for death due to infection, and longer duration of treat- 
ment and treatment with flucloxacillin were significant 
protective factors. These findings were not unexpected; 
older patients are more likely to be immunocom- 
promised, flucloxacilhn is a potent antistaphylococcal 
agent and treatment regimens are often given for 
prolonged periods. 
The presence of an intravascular device and the 
presence of a skin lesion were significant protective 
factors. We suspect that these findings arose because the 
variables acted as ‘markers’ for subsets of patients who 
were less likely to die from infection. For example, the 
presence of an intravascular device may have been a 
marker for an infection that arose in the context of a 
removable focus of infection, and the presence of a skin 
lesion may have been a marker for bacteremia derived 
from a primary skin or wound infection which 
developed in an otherwise healthy individual in whom 
the prognosis would be expected to be good. This 
interpretation is supported by a previous study which 
found the only factor predictive of the outcome was the 
presence of a source of bacteremia. Patients in whom 
the source of bacteremia was defined had a better 
prognosis with regard to mortality rate, incidence of 
endocarditis and secondary foci [24]. 
Factors that were associated with death due to 
infection were not found to be associated with relapse, 
suggesting that the circumstances which predispose 
patients to experience these unfavorable outcomes may 
be a e r e n t .  Moreover, the treatment combination of 
flucloxacib and fusidic acid appeared to give rise to 
about a 70% reduction in the risk of relapse, although 
ths was not reflected in a significant decrease in the rate 
of relapse during the study period, or in a significant 
decrease in DRI. 
It has not previously been shown that the com- 
bination of flucloxacdhn plus fusidic acid is superior to 
other therapy for the treatment of S. aureus bacteremia. 
Fusidic acid is an effective narrow-spectrum antibiotic 
with excellent activity against S. aureus, with MICs in 
the range 0.03-0.25 mg/L. It has been in clinical use 
in the UK for 30 years and is regarded as a usefd 
antistaphylococcal antibiotic [32]. Fusidic acid is very 
well absorbed afier oral administration and shows 
high and long-lasting serum levels with therapeutic 
concentrations in bone tissue, synovial fluid, heart 
tissue and bronchial secretions. It has a proven ability 
to penetrate into avascular sites [33], and perhaps it is 
this latter property that enables it to act against possible 
secondary foci of infection in patients with S. aureus 
bacteremia and thus prevent relapse. 
Many advocate short-course therapy in specific 
situations such as catheter-related bacteremia [ll- 
13,151 or in uncomplicated right-sided endocarditis in 
intravenous drug users [14,16]. Others disagree and feel 
short-course therapy is inadequate and results in 
unacceptable rates of complications and relapses 
[17,18]. Others conclude that available data are not 
sufficient and the optimum duration of therapy remains 
unknown [8]. Early studies reported a risk of endo- 
carditis of 60% with S. aureus bacteremia and thus long 
term parented antibiotic therapy became standard 
practice. More recent studies report an overall in- 
cidence of endocarhtis of 10% or less [12,24,25]. Our 
study showed an incidence of 8.5%. These low rates 
of endocarditis have led to guidelines for short-term 
treatment (2-3 weeks) or long-term treatment (4-6 
weeks), dependmg on whether endocarditis is likely to 
be present [25]. Use of the Nolan and Beaty criteria 
have been found usefil in some at-risk populations 
[1,28] but not in others [18,34]. This study did show 
that patients were less likely to die of infection when 
treatment was continued for longer, although this 
finding is Wicult to interpret. From a statistical point 
of view, the result is valid for treatment durations 
withn the range of the original data, in this case up to 
200 days. However, almost 90% of patients were treated 
for less than 6 weeks and the finding is based mainly on 
the data from these patients. Therefore we conclude 
that an increase in the duration of treatment up to 6 
G o s d e n  e t  a l :  O u t c o m e  i n  p a t i e n t s  t r e a t e d  for S t a p h .  a u r e u s  b a c t e r e m i a  39 
weeks confers protection against death from infection, 
but that the question of whether longer durations 
of treatment confer an additional benefit remains 
unanswered. Furthermore, t h s  general conclusion does 
not rule out the possibility of interactions between 
duration of treatment and subsets of the population. For 
example, periods of treatment much shorter than 6 
weeks may be adequate for young and otherwise 
healthy patients with catheter-related bacteremia. Our 
study did not have sufficient power to investigate such 
interactions. 
The findings of a retrospective cross-sectional study 
must always be interpreted with caution, since this type 
of study design is susceptible to confounding and bias. 
Our analyses tried to take account of these alternative 
explanations. Confounding was investigated by model- 
ing the effects of a wide range of other variables, 
characterizing demographic details, co-morbidity and 
aspects of treatment, none ofwhich significantly altered 
the protective effect of the treatment combination of 
flucloxacillin and hsidic acid on relapse. The possibility 
of bias is more difficult to exclude, since data were 
unavailable for a substantial proportion of cases, the 
information obtained was dependent on the documen- 
tation available and the outcome for each patient was 
not ‘blinded’ to the treatment the patient received. 
However, it was reassuring that the findings were 
unaltered when patients not treated with flucloxacillin 
were omitted from the analysis. The results of this study 
suggest that a prospective randomized control trial 
based in a number of centers should be carried out to 
compare the use of flucloxacillin plus fusidic acid with 
another antibiotic regimen, such as flucloxacillin alone, 
for the treatment of S. uureus bacteremia. 
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